// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Baseline and longitudinal urinary eicosanoid profiles for molecular sub-phenotyping in the U-BIOPRED study

Johan Kolmert - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Late Breaking Abstract - Matrix metalloproteinases in serum and sputum reflect distinct processes of relevance to asthma

Anna James - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Prednisolone

Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study

Ian Douglas Pavord - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Dupilumab

Late Breaking Abstract - Microbiome-driven clusters in severe asthma derived from induced sputum: identification and stability over time

Mahmoud Ismael Abdelaziz Ibrahim - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

The potential role of Neuromedin U in human type-2 immunity

YUAN YE - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Potential bed-day savings in patients admitted unnecessarily for pleural invesigation

Jenny Ferguson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The effectiveness and cost-effectiveness of hospital palliative care for adults affected by advanced illness and breathlessness: a systematic review and meta-analysis

Sabrina Bajwah - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Rocket Pleural Vent in Pneumothorax

Matthew Knight - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pneumothorax

N/A

An integrated approach to improving the safe use and prescription of oxygen

David Tarpey - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist

Lorcan McGarvey - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Gefapixant

Relationship between health-related quality of life and objective cough frequency in a phase 2b trial of gefapixant

Surinder S. Birring - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Gefapixant

Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist

Surinder S. Birring - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Gefapixant

Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial

Jaclyn Smith - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Orvepitant

Aspiration in children with trisomy 21

Christopher Edwards - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Down syndrome

N/A

The impact of a consultant led inreach service on patient transfer to respiratory wards: A Quality Improvement Project

Sajeev Ranmuthu - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial

Bruce Trapnell - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary alveolar proteinosis

Molgramostim

Evaluating the effect of long-term idebenone treatment on respiratory morbidity in patients with Duchenne muscular dystrophy (DMD)

Oscar Henry Mayer - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Duchenne muscular dystrophy

Idebenone

Applying machine learning to evaluate dyspnoea in athletes with exercise-induced bronchoconstriction

Oliver J Price - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Bronchodilation increases exercise endurance in COPD patients with sustained concavity in the spontaneous expiratory flow volume loop

Min Cao - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Increasing CPAP (Continuous Positive Airway Pressure) leads to increasing trans-pulmonary pressure with increased activity of the abdominal wall muscles to aid Expiration

Michael Apps - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved